A randomized controlled trial in China reveals that HCC surveillance with testing of serum AFP and performance of abdominal ultrasound (US) at repeated 6-month intervals significantly improves patient survival [25], [26]. The gene discussed is AFP; the disease is hepatocellular carcinoma.